On September 7, 2022 TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, reported that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate at the following upcoming investor conferences and provide a company overview (Press release, Tracon Pharmaceuticals, SEP 7, 2022, View Source [SID1234619169]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo 2022 Healthcare Conference – September 9th at 9:10am EDT
H.C. Wainwright 24th Annual Global Investment Conference – September 14th at 3:00pm EDT
RW Baird 2022 Global Healthcare Conference – September 14th at 11:25am EDT
To access a live webcast or replay of the Wells Fargo and H.C. Wainwright conference presentations, please visit the "Events and Presentations" page within the "Investors" section of the TRACON Pharmaceuticals website at www.traconpharma.com.